• +1-646-491-9876
    • +91-20-67278686

    Search

    Nasopharyngeal Cancer - Pipeline Review, H1 2017

    Nasopharyngeal Cancer - Pipeline Review, H1 2017

    • Report Code ID: RW0001709473
    • Category Pharmaceuticals
    • No. of Pages 258
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Nasopharyngeal Cancer - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2017, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

    Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 12, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 7, 2 and 6 molecules, respectively.

    Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Nasopharyngeal Cancer - Overview 7
    Nasopharyngeal Cancer - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 15
    Nasopharyngeal Cancer - Therapeutics Assessment 16
    Assessment by Target 16
    Assessment by Mechanism of Action 19
    Assessment by Route of Administration 22
    Assessment by Molecule Type 24
    Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 26
    Advenchen Laboratories LLC 26
    Ambrx Inc 26
    arGEN-X BV 27
    Ascentage Pharma Group Corp Ltd 27
    Atara Biotherapeutics Inc 28
    AVEO Pharmaceuticals Inc 28
    BeiGene Ltd 29
    Betta Pharmaceuticals Co Ltd 29
    BioDiem Ltd 30
    Biomics Biotechnologies Co Ltd 30
    CBT Pharmaceuticals Inc 31
    Celgene Corp 31
    Cell Medica Ltd 32
    F. Hoffmann-La Roche Ltd 32
    GlaxoSmithKline Plc 33
    MedImmune LLC 33
    Merck & Co Inc 34
    Merck KGaA 34
    Millennium Pharmaceuticals Inc 35
    Neonc Technologies Inc 35
    Novartis AG 36
    Ono Pharmaceutical Co Ltd 36
    Sapvax 37
    Tessa Therapeutics Pte Ltd 37
    Theravectys SA 38
    Viracta Therapeutics Inc 38
    Yabao Pharmaceutical Group Co Ltd 39
    Nasopharyngeal Cancer - Drug Profiles 40
    alisertib - Drug Profile 40
    Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile 46
    apatinib - Drug Profile 47
    APG-1387 - Drug Profile 51
    ARGX-110 - Drug Profile 52
    ATA-129 - Drug Profile 57
    atezolizumab - Drug Profile 60
    avelumab - Drug Profile 77
    azacitidine - Drug Profile 86
    baltaleucel-T - Drug Profile 92
    bevacizumab - Drug Profile 94
    BGBA-317 - Drug Profile 106
    CBT-501 - Drug Profile 108
    Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile 109
    Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer - Drug Profile 110
    Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Carcinoma - Drug Profile 111
    Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile 112
    Cellular Immunotherapy for Oncology - Drug Profile 113
    Cellular Immunotherapy for Oncology - Drug Profile 114
    Cellular Immunotherapy for Oncology - Drug Profile 116
    Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile 117
    Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 118
    Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile 119
    DC-120 - Drug Profile 120
    donafenib - Drug Profile 121
    durvalumab + tremelimumab - Drug Profile 122
    EBViNT - Drug Profile 127
    Epstein-Barr virus vaccine - Drug Profile 128
    ficlatuzumab - Drug Profile 129
    GSK-2849330 - Drug Profile 132
    icotinib hydrochloride - Drug Profile 133
    JS-001 - Drug Profile 135
    MAK-683 - Drug Profile 136
    Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile 137
    Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 138
    MVA vaccine - Drug Profile 139
    NEO-212 - Drug Profile 140
    nimotuzumab - Drug Profile 141
    nivolumab - Drug Profile 145
    PDR-001 - Drug Profile 185
    pembrolizumab - Drug Profile 187
    RO-5203280 - Drug Profile 235
    Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer - Drug Profile 236
    SV-638 - Drug Profile 237
    TT-10 - Drug Profile 238
    Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 239
    Vaccine for Oncology - Drug Profile 240
    Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 241
    Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma - Drug Profile 242
    VRx-3996 - Drug Profile 243
    Nasopharyngeal Cancer - Dormant Projects 245
    Nasopharyngeal Cancer - Discontinued Products 246
    Nasopharyngeal Cancer - Product Development Milestones 247
    Featured News & Press Releases 247
    Appendix 253
    Methodology 253
    Coverage 253
    Secondary Research 253
    Primary Research 253
    Expert Panel Validation 253
    Contact Us 253
    Disclaimer 254

    List of Tables

    Number of Products under Development for Nasopharyngeal Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
    Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H1 2017
    Nasopharyngeal Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by Celgene Corp, H1 2017
    Nasopharyngeal Cancer - Pipeline by Cell Medica Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
    Nasopharyngeal Cancer - Pipeline by MedImmune LLC, H1 2017
    Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by Merck KGaA, H1 2017
    Nasopharyngeal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by Novartis AG, H1 2017
    Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by Sapvax, H1 2017
    Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017
    Nasopharyngeal Cancer - Pipeline by Theravectys SA, H1 2017
    Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, H1 2017
    Nasopharyngeal Cancer - Pipeline by Yabao Pharmaceutical Group Co Ltd, H1 2017
    Nasopharyngeal Cancer - Dormant Projects, H1 2017
    Nasopharyngeal Cancer - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Nasopharyngeal Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advenchen Laboratories LLC
    Ambrx Inc
    arGEN-X BV
    Ascentage Pharma Group Corp Ltd
    Atara Biotherapeutics Inc
    AVEO Pharmaceuticals Inc
    BeiGene Ltd
    Betta Pharmaceuticals Co Ltd
    BioDiem Ltd
    Biomics Biotechnologies Co Ltd
    CBT Pharmaceuticals Inc
    Celgene Corp
    Cell Medica Ltd
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    MedImmune LLC
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    Neonc Technologies Inc
    Novartis AG
    Ono Pharmaceutical Co Ltd
    Sapvax
    Tessa Therapeutics Pte Ltd
    Theravectys SA
    Viracta Therapeutics Inc
    Yabao Pharmaceutical Group Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//nasopharyngeal-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//nasopharyngeal-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//nasopharyngeal-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments